Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Plbd1 (phospholipase B domain containing 1) Rattus norvegicus
Analyze
Symbol:
Plbd1
Name:
phospholipase B domain containing 1
RGD ID:
1308734
Description:
Predicted to have phospholipase activity. Predicted to be involved in phospholipid catabolic process. Predicted to localize to extracellular space. Orthologous to human PLBD1 (phospholipase B domain containing 1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole; 6-propyl-2-thiouracil.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
LAMA-like protein 1; lamina ancestor homolog 1; LOC297694; phospholipase B domain-containing protein 1; phospholipase B-like 1; putative phospholipase B-like 1; RGD1308734; similar to RIKEN cDNA 1100001H23
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
PLBD1 (phospholipase B domain containing 1) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Plbd1 (phospholipase B domain containing 1) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, PhylomeDB, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Plbd1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
PLBD1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
PLBD1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Plbd1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
PLBD1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
PLBD1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Plbd1 (phospholipase B domain containing 1) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Mus musculus (house mouse):
Plbd1 (phospholipase B domain containing 1)
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Homo sapiens (human):
PLBD1 (phospholipase B domain containing 1)
Alliance
DIOPT (Ensembl Compara|HGNC|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Danio rerio (zebrafish):
plbd1 (phospholipase B domain containing 1)
Alliance
DIOPT (PhylomeDB|TreeFam)
Danio rerio (zebrafish):
si:ch73-139e5.2
Alliance
DIOPT (PhylomeDB|TreeFam)
Drosophila melanogaster (fruit fly):
lama
Alliance
DIOPT (Ensembl Compara|InParanoid|OMA|OrthoInspector|TreeFam)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl mRatBN7.2 4 169,472,983 - 169,529,277 (-) NCBI Rnor_6.0 Ensembl 4 170,564,367 - 170,620,703 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_6.0 4 170,564,387 - 170,620,681 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_5.0 4 234,823,110 - 234,879,736 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 4 173,611,465 - 173,667,759 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 4 173,856,588 - 173,912,883 (-) NCBI Celera 4 158,056,782 - 158,113,069 (-) NCBI Celera Cytogenetic Map 4 q43 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Disease Annotations - CTD
2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of PLBD1 mRNA CTD PMID:26232522 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1318682 6480464 Tetrachlorodibenzodioxin affects the expression of PLBD1 mRNA CTD PMID:26377647 2-hydroxypropanoic acid decreases expression ISO RGD:1605619 6480464 Lactic Acid results in decreased expression of PLBD1 mRNA CTD PMID:30851411 4,4'-sulfonyldiphenol increases expression ISO RGD:1318682 6480464 bis4-hydroxyphenylsulfone results in increased expression of PLBD1 mRNA CTD PMID:30951980 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid increases expression ISO RGD:1605619 6480464 Am 580 results in increased expression of PLBD1 mRNA CTD PMID:16982809 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression EXP 6480464 Omeprazole affects the expression of PLBD1 mRNA CTD PMID:19483382 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of PLBD1 mRNA CTD PMID:19483382 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of PLBD1 mRNA CTD PMID:28959563 aflatoxin B1 decreases expression ISO RGD:1318682 6480464 Aflatoxin B1 results in decreased expression of PLBD1 mRNA CTD PMID:19770486 all-trans-retinoic acid increases expression ISO RGD:1605619 6480464 Tretinoin results in increased expression of PLBD1 mRNA CTD PMID:21934132 amiodarone affects expression EXP 6480464 Amiodarone affects the expression of PLBD1 mRNA CTD PMID:19483382 arsane multiple interactions ISO RGD:1605619 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of PLBD1 mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:1605619 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of PLBD1 mRNA CTD PMID:32525701 benzbromarone affects expression EXP 6480464 Benzbromarone affects the expression of PLBD1 mRNA CTD PMID:19483382 benzo[a]pyrene affects methylation ISO RGD:1605619 6480464 Benzoapyrene affects the methylation of PLBD1 promoter CTD PMID:27901495 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1605619 6480464 Diethylhexyl Phthalate results in decreased expression of PLBD1 mRNA CTD PMID:31163220 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of PLBD1 mRNA CTD PMID:25181051 cadmium dichloride increases methylation EXP 6480464 Cadmium Chloride results in increased methylation of PLBD1 promoter CTD PMID:22457795 carbon nanotube increases expression ISO RGD:1318682 6480464 Nanotubes, Carbon analog results in increased expression of PLBD1 mRNA CTD PMID:25554681 chloroprene decreases expression ISO RGD:1318682 6480464 Chloroprene results in decreased expression of PLBD1 mRNA CTD PMID:23125180 clofibrate affects expression EXP 6480464 Clofibrate affects the expression of PLBD1 mRNA CTD PMID:19483382 clofibrate decreases expression ISO RGD:1318682 6480464 Clofibrate results in decreased expression of PLBD1 mRNA CTD PMID:17585979 clothianidin decreases expression ISO RGD:1605619 6480464 clothianidin results in decreased expression of PLBD1 mRNA CTD PMID:31626844 cyproconazole increases expression ISO RGD:1318682 6480464 cyproconazole results in increased expression of PLBD1 mRNA CTD PMID:22334560 dibutyl phthalate decreases expression ISO RGD:1318682 6480464 Dibutyl Phthalate results in decreased expression of PLBD1 mRNA CTD PMID:21266533 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of PLBD1 mRNA CTD PMID:21266533 diuron decreases expression EXP 6480464 Diuron results in decreased expression of PLBD1 mRNA CTD PMID:25152437 dorsomorphin multiple interactions ISO RGD:1605619 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 doxorubicin affects expression ISO RGD:1605619 6480464 Doxorubicin affects the expression of PLBD1 mRNA CTD PMID:29803840 entinostat increases expression ISO RGD:1605619 6480464 entinostat results in increased expression of PLBD1 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1605619 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLBD1 mRNA CTD PMID:27188386 epoxiconazole increases expression ISO RGD:1318682 6480464 epoxiconazole results in increased expression of PLBD1 mRNA CTD PMID:22334560 folic acid increases expression ISO RGD:1318682 6480464 Folic Acid results in increased expression of PLBD1 mRNA CTD PMID:25629700 gefitinib affects response to substance ISO RGD:1605619 6480464 PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 genistein increases expression ISO RGD:1318682 6480464 Genistein results in increased expression of PLBD1 mRNA CTD PMID:32186404 indole-3-methanol affects expression EXP 6480464 indole-3-carbinol affects the expression of PLBD1 mRNA CTD PMID:21396975 L-ethionine affects expression EXP 6480464 Ethionine affects the expression of PLBD1 mRNA CTD PMID:19483382 menadione affects expression ISO RGD:1605619 6480464 Vitamin K 3 affects the expression of PLBD1 mRNA CTD PMID:20044591 methapyrilene increases expression EXP 6480464 Methapyrilene results in increased expression of PLBD1 mRNA CTD PMID:30467583 methylmercury chloride decreases expression ISO RGD:1605619 6480464 methylmercuric chloride results in decreased expression of PLBD1 mRNA CTD PMID:23179753 monosodium L-glutamate multiple interactions ISO RGD:1318682 6480464 [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of PLBD1 mRNA CTD PMID:22078008 N-methyl-4-phenylpyridinium increases expression EXP 6480464 1-Methyl-4-phenylpyridinium results in increased expression of PLBD1 mRNA CTD PMID:28801915 nefazodone decreases expression EXP 6480464 nefazodone results in decreased expression of PLBD1 mRNA CTD PMID:24136188 nimesulide decreases expression EXP 6480464 nimesulide results in decreased expression of PLBD1 mRNA CTD PMID:24136188 omeprazole affects expression EXP 6480464 Omeprazole affects the expression of PLBD1 mRNA CTD PMID:19483382 panobinostat multiple interactions ISO RGD:1605619 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of PLBD1 mRNA CTD PMID:27188386 panobinostat increases expression ISO RGD:1605619 6480464 panobinostat results in increased expression of PLBD1 mRNA CTD PMID:26272509 perfluorooctanoic acid increases expression ISO RGD:1318682 6480464 perfluorooctanoic acid results in increased expression of PLBD1 mRNA CTD PMID:30711707 pirinixic acid multiple interactions ISO RGD:1318682 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of PLBD1 mRNA CTD PMID:19710929 pirinixic acid increases expression ISO RGD:1318682 6480464 pirinixic acid results in increased expression of PLBD1 mRNA CTD PMID:20813756 , PMID:23811191 pirinixic acid affects expression EXP 6480464 pirinixic acid affects the expression of PLBD1 mRNA CTD PMID:19483382 propiconazole increases expression ISO RGD:1318682 6480464 propiconazole results in increased expression of PLBD1 mRNA CTD PMID:21278054 , PMID:22334560 rac-lactic acid decreases expression ISO RGD:1605619 6480464 Lactic Acid results in decreased expression of PLBD1 mRNA CTD PMID:30851411 SB 431542 multiple interactions ISO RGD:1605619 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 sodium arsenate multiple interactions ISO RGD:1605619 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in decreased expression of PLBD1 mRNA CTD PMID:32525701 sodium fluoride increases expression ISO RGD:1318682 6480464 Sodium Fluoride results in increased expression of PLBD1 protein CTD PMID:28918527 sunitinib decreases expression ISO RGD:1605619 6480464 Sunitinib results in decreased expression of PLBD1 mRNA CTD PMID:31533062 tert-butyl hydroperoxide decreases expression ISO RGD:1605619 6480464 tert-Butylhydroperoxide results in decreased expression of PLBD1 mRNA CTD PMID:15336504 Tesaglitazar increases expression EXP 6480464 tesaglitazar results in increased expression of PLBD1 mRNA CTD PMID:21515302 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of PLBD1 mRNA CTD PMID:31150632 tetrachloromethane decreases expression ISO RGD:1318682 6480464 Carbon Tetrachloride results in decreased expression of PLBD1 mRNA CTD PMID:29987408 thioacetamide affects expression EXP 6480464 Thioacetamide affects the expression of PLBD1 mRNA CTD PMID:19483382 trovafloxacin decreases expression EXP 6480464 trovafloxacin results in decreased expression of PLBD1 mRNA CTD PMID:24136188 tungsten decreases expression ISO RGD:1318682 6480464 Tungsten results in decreased expression of PLBD1 mRNA CTD PMID:30912803 valproic acid decreases expression ISO RGD:1605619 6480464 Valproic Acid results in decreased expression of PLBD1 mRNA CTD PMID:29154799 vinclozolin increases methylation EXP 6480464 vinclozolin results in increased methylation of PLBD1 gene CTD PMID:31079544
2,3,7,8-tetrachlorodibenzodioxine (EXP,ISO) 2-hydroxypropanoic acid (ISO) 4,4'-sulfonyldiphenol (ISO) 4-\{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino\}benzoic acid (ISO) 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole (EXP) 6-propyl-2-thiouracil (EXP) acrylamide (EXP) aflatoxin B1 (ISO) all-trans-retinoic acid (ISO) amiodarone (EXP) arsane (ISO) arsenic atom (ISO) benzbromarone (EXP) benzo[a]pyrene (ISO) bis(2-ethylhexyl) phthalate (ISO) bisphenol A (EXP) cadmium dichloride (EXP) carbon nanotube (ISO) chloroprene (ISO) clofibrate (EXP,ISO)
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
2316958 Gluco58 Glucose level QTL 58 10 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 4 7850904 182171018 Rat 1576316 Ept5 Estrogen-induced pituitary tumorigenesis QTL 5 3.8 pituitary gland mass (VT:0010496) pituitary gland wet weight (CMO:0000853) 4 84475257 178931073 Rat 1358364 Sradr4 Stress Responsive Adrenal Weight QTL 4 4.92 adrenal gland mass (VT:0010420) both adrenal glands wet weight (CMO:0000164) 4 128602727 173602727 Rat 724558 Plsm2 Polydactyly-luxate syndrome (PLS) morphotypes QTL 2 0.0003 hindlimb integrity trait (VT:0010563) hind foot phalanges count (CMO:0001949) 4 131834282 176834282 Rat 1549827 Scl46 Serum cholesterol level QTL 46 3.5 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 4 131864442 176864442 Rat 2303623 Vencon2 Ventilatory control QTL 2 3.8 respiration trait (VT:0001943) minute ventilation (VE) (CMO:0000132) 4 134917642 179917642 Rat 61362 Oia2 Oil induced arthritis QTL 2 0.001 joint integrity trait (VT:0010548) joint inflammation composite score (CMO:0000919) 4 136351734 174694858 Rat 1298524 Oia8 Oil induced arthritis QTL 8 joint integrity trait (VT:0010548) joint inflammation composite score (CMO:0000919) 4 136351734 174694858 Rat 1331738 Bp209 Blood pressure QTL 209 2.979 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 4 136351734 180689124 Rat 2293659 Bmd35 Bone mineral density QTL 35 4.5 0.0001 femur strength trait (VT:0010010) femoral neck ultimate force (CMO:0001703) 4 136908430 182878540 Rat 1578674 Bmd12 Bone mineral density QTL 12 3.8 femur mineral mass (VT:0010011) cortical volumetric bone mineral density (CMO:0001730) 4 137171018 182171018 Rat 634342 Cia24 Collagen induced arthritis QTL 24 4.5 joint integrity trait (VT:0010548) joint inflammation composite score (CMO:0000919) 4 145373934 176509907 Rat 6478693 Anxrr32 Anxiety related response QTL 32 0.00092 locomotor behavior trait (VT:0001392) measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957) 4 145547014 184226339 Rat 6478700 Anxrr33 Anxiety related response QTL 33 0.00896 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 145547014 184226339 Rat 6478718 Anxrr34 Anxiety related response QTL 34 0.00896 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 145547014 184226339 Rat 6478748 Anxrr42 Anxiety related response QTL 42 0.28008 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 145547014 184226339 Rat 6478754 Anxrr43 Anxiety related response QTL 43 0.14035 locomotor behavior trait (VT:0001392) distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493) 4 145547014 184226339 Rat 10401796 Kidm48 Kidney mass QTL 48 kidney mass (VT:0002707) both kidneys wet weight (CMO:0000085) 4 146497452 184226339 Rat 6478782 Anxrr52 Anxiety related response QTL 52 0.02091 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 6478785 Anxrr53 Anxiety related response QTL 53 0.01397 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 6478720 Alc23 Alcohol consumption QTL 23 0.00509 drinking behavior trait (VT:0001422) ethanol drink intake rate to body weight ratio (CMO:0001616) 4 155386197 184226339 Rat 6478728 Anxrr36 Anxiety related response QTL 36 0.01061 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 6478733 Anxrr37 Anxiety related response QTL 37 0.00095 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 6478737 Anxrr38 Anxiety related response QTL 38 0.00159 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 6478757 Anxrr44 Anxiety related response QTL 44 0.01087 locomotor behavior trait (VT:0001392) amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958) 4 155386197 184226339 Rat 10053718 Scort25 Serum corticosterone level QTL 25 2.15 0.0097 blood corticosterone amount (VT:0005345) plasma corticosterone level (CMO:0001173) 4 156855449 184226339 Rat 1300109 Rf13 Renal function QTL 13 3.91 renal blood flow trait (VT:2000006) absolute change in renal blood flow rate (CMO:0001168) 4 157423126 184226339 Rat
